Cargando…

Pediatric pharmacovigilance in an institute of national importance: Journey has just begun

OBJECTIVE: The objective of this study is to determine the nature and severity of adverse drug reactions (ADRs) in pediatric patients. MATERIALS AND METHODS: In this retrospective cohort study, we extracted the data from all the available pediatric ADR forms submitted to ADR monitoring center (AMC)...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharma, Pramod Kumar, Misra, Arup Kumar, Gupta, Neeraj, Khera, Daisy, Gupta, Ajay, Khera, Pushpinder
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5830850/
https://www.ncbi.nlm.nih.gov/pubmed/29515280
http://dx.doi.org/10.4103/ijp.IJP_256_17
_version_ 1783303078244515840
author Sharma, Pramod Kumar
Misra, Arup Kumar
Gupta, Neeraj
Khera, Daisy
Gupta, Ajay
Khera, Pushpinder
author_facet Sharma, Pramod Kumar
Misra, Arup Kumar
Gupta, Neeraj
Khera, Daisy
Gupta, Ajay
Khera, Pushpinder
author_sort Sharma, Pramod Kumar
collection PubMed
description OBJECTIVE: The objective of this study is to determine the nature and severity of adverse drug reactions (ADRs) in pediatric patients. MATERIALS AND METHODS: In this retrospective cohort study, we extracted the data from all the available pediatric ADR forms submitted to ADR monitoring center (AMC) from May 2014 to December 2016. The data including nature, frequency, causality (World Health Organization [WHO] causality scale), and the severity (Hartwig and Siegel scale for severity) of ADR were extracted. We also assessed the preventability of the event on modified Schumock and Thornton scale of ADR preventability. RESULTS: There were a total of 20 pediatric ADRs reported during this period. Nearly two-thirds of the ADRs occurred in patients who were receiving multiple drugs (polytherapy). Antimicrobial agents were the most commonly implicated drugs. The most common ADRs were skin rash (maculopapular, erythematous, and urticaria, itching, etc.). The severity and preventability scales indicated that most reactions (18/20) were moderate in nature and all were preventable. Four reactions were “certainly” and ten ADRs were “probably” related to the suspected drug as determined by the WHO causality assessment. CONCLUSION: Frequency of ADR increased with number of medications patient was receiving. Health-care providers (HCPs) involved in the care of children must be aware of this fact and should use additional drugs when absolutely necessary. They should be involved in pharmacovigilance program by exchanging and updating each other through sharing constructive information, communication, and education concerning the appropriate use of drugs in children. Pediatric pharmacovigilance is the need of the hour and should be given utmost importance for monitoring the safety of drugs in children. Motivating HCPs for voluntary reporting of ADRs for preventing the morbidity and mortality in this vulnerable population could be of immense importance.
format Online
Article
Text
id pubmed-5830850
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-58308502018-03-07 Pediatric pharmacovigilance in an institute of national importance: Journey has just begun Sharma, Pramod Kumar Misra, Arup Kumar Gupta, Neeraj Khera, Daisy Gupta, Ajay Khera, Pushpinder Indian J Pharmacol Research Article OBJECTIVE: The objective of this study is to determine the nature and severity of adverse drug reactions (ADRs) in pediatric patients. MATERIALS AND METHODS: In this retrospective cohort study, we extracted the data from all the available pediatric ADR forms submitted to ADR monitoring center (AMC) from May 2014 to December 2016. The data including nature, frequency, causality (World Health Organization [WHO] causality scale), and the severity (Hartwig and Siegel scale for severity) of ADR were extracted. We also assessed the preventability of the event on modified Schumock and Thornton scale of ADR preventability. RESULTS: There were a total of 20 pediatric ADRs reported during this period. Nearly two-thirds of the ADRs occurred in patients who were receiving multiple drugs (polytherapy). Antimicrobial agents were the most commonly implicated drugs. The most common ADRs were skin rash (maculopapular, erythematous, and urticaria, itching, etc.). The severity and preventability scales indicated that most reactions (18/20) were moderate in nature and all were preventable. Four reactions were “certainly” and ten ADRs were “probably” related to the suspected drug as determined by the WHO causality assessment. CONCLUSION: Frequency of ADR increased with number of medications patient was receiving. Health-care providers (HCPs) involved in the care of children must be aware of this fact and should use additional drugs when absolutely necessary. They should be involved in pharmacovigilance program by exchanging and updating each other through sharing constructive information, communication, and education concerning the appropriate use of drugs in children. Pediatric pharmacovigilance is the need of the hour and should be given utmost importance for monitoring the safety of drugs in children. Motivating HCPs for voluntary reporting of ADRs for preventing the morbidity and mortality in this vulnerable population could be of immense importance. Medknow Publications & Media Pvt Ltd 2017 /pmc/articles/PMC5830850/ /pubmed/29515280 http://dx.doi.org/10.4103/ijp.IJP_256_17 Text en Copyright: © 2018 Indian Journal of Pharmacology http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
spellingShingle Research Article
Sharma, Pramod Kumar
Misra, Arup Kumar
Gupta, Neeraj
Khera, Daisy
Gupta, Ajay
Khera, Pushpinder
Pediatric pharmacovigilance in an institute of national importance: Journey has just begun
title Pediatric pharmacovigilance in an institute of national importance: Journey has just begun
title_full Pediatric pharmacovigilance in an institute of national importance: Journey has just begun
title_fullStr Pediatric pharmacovigilance in an institute of national importance: Journey has just begun
title_full_unstemmed Pediatric pharmacovigilance in an institute of national importance: Journey has just begun
title_short Pediatric pharmacovigilance in an institute of national importance: Journey has just begun
title_sort pediatric pharmacovigilance in an institute of national importance: journey has just begun
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5830850/
https://www.ncbi.nlm.nih.gov/pubmed/29515280
http://dx.doi.org/10.4103/ijp.IJP_256_17
work_keys_str_mv AT sharmapramodkumar pediatricpharmacovigilanceinaninstituteofnationalimportancejourneyhasjustbegun
AT misraarupkumar pediatricpharmacovigilanceinaninstituteofnationalimportancejourneyhasjustbegun
AT guptaneeraj pediatricpharmacovigilanceinaninstituteofnationalimportancejourneyhasjustbegun
AT kheradaisy pediatricpharmacovigilanceinaninstituteofnationalimportancejourneyhasjustbegun
AT guptaajay pediatricpharmacovigilanceinaninstituteofnationalimportancejourneyhasjustbegun
AT kherapushpinder pediatricpharmacovigilanceinaninstituteofnationalimportancejourneyhasjustbegun